Home / Products / Vaginal atrophy

Vaginal atrophy

In conjunction with the menopause, many women develop vaginal atrophy. It is the decreasing estrogen production occurring during menopause that results in vaginal atrophy, as estrogen stimulates the growth of the mucosa.

Symptoms such as vaginal dryness, irritation and itching are common in women with vaginal atrophy. The risk of developing infections is increased and sexual intercourse can be painful which affects quality of life negatively.

Frequently these problems can be improved by means of estrogen treatment in the form of tablets, patches or local treatment with creams or vaginal inserts. However, not all women can or are willing to use estrogen. Based on clinical studies with women suffering from vaginal atrophy, PEPTONIC’s VagiVital™ , which is a hormone free product, offers good symptom relief, and hence, an alternative to estrogens.

Oxytocin, which is a peptide hormone produced in the body, has been shown to stimulate the growth of the vaginal mucosa. Hence, topical application of oxytocin may offer a safe and tolerable alternative to estrogens in alleviating symptoms associated with vaginal atrophy.

Treatment with oxytocin

The reduction of the number of cell layers and the lack of mature cells in the vaginal mucous membrane during and after menopause.

A short term treatment with oxytocin can increase the number of cell layers and the number of mature cells in the vaginal mucosa.


Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.